These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The molecular genetic basis and diagnosis of familial hypercholesterolemia in Denmark. Jensen HK Dan Med Bull; 2002 Nov; 49(4):318-45. PubMed ID: 12553167 [TBL] [Abstract][Full Text] [Related]
5. Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia. Afanasieva OI; Ezhov MV; Razova OA; Afanasieva MI; Utkina EA; Pokrovsky SN Atherosclerosis; 2018 Oct; 277():477-482. PubMed ID: 30270088 [TBL] [Abstract][Full Text] [Related]
6. Causative mutations and premature cardiovascular disease in patients with heterozygous familial hypercholesterolaemia. Rubba P; Gentile M; Marotta G; Iannuzzi A; Sodano M; De Simone B; Jossa F; Iannuzzo G; Giacobbe C; Di Taranto MD; Fortunato G Eur J Prev Cardiol; 2017 Jul; 24(10):1051-1059. PubMed ID: 28353356 [TBL] [Abstract][Full Text] [Related]
7. Homozygous Familial Hypercholesterolemia in Spain: Prevalence and Phenotype-Genotype Relationship. Sánchez-Hernández RM; Civeira F; Stef M; Perez-Calahorra S; Almagro F; Plana N; Novoa FJ; Sáenz-Aranzubía P; Mosquera D; Soler C; Fuentes FJ; Brito-Casillas Y; Real JT; Blanco-Vaca F; Ascaso JF; Pocovi M Circ Cardiovasc Genet; 2016 Dec; 9(6):504-510. PubMed ID: 27784735 [TBL] [Abstract][Full Text] [Related]
9. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602 [TBL] [Abstract][Full Text] [Related]
15. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Austin MA; Hutter CM; Zimmern RL; Humphries SE Am J Epidemiol; 2004 Sep; 160(5):407-20. PubMed ID: 15321837 [TBL] [Abstract][Full Text] [Related]
16. Familial Hypercholesterolemia: Global Burden and Approaches. Tokgozoglu L; Kayikcioglu M Curr Cardiol Rep; 2021 Sep; 23(10):151. PubMed ID: 34480646 [TBL] [Abstract][Full Text] [Related]
17. Portuguese Familial Hypercholesterolemia Study: presentation of the study and preliminary results. Bourbon M; Rato Q; Rev Port Cardiol; 2006 Nov; 25(11):999-1013. PubMed ID: 17274457 [TBL] [Abstract][Full Text] [Related]
18. Familial hypercholesterolemia: Review of diagnosis, screening, and treatment. Turgeon RD; Barry AR; Pearson GJ Can Fam Physician; 2016 Jan; 62(1):32-7. PubMed ID: 26796832 [TBL] [Abstract][Full Text] [Related]
19. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Raal FJ; Santos RD Atherosclerosis; 2012 Aug; 223(2):262-8. PubMed ID: 22398274 [TBL] [Abstract][Full Text] [Related]
20. Familial hypercholesterolemia: Detect, treat, and ask about family. Shah NP; Ahmed HM; Wilson Tang WH Cleve Clin J Med; 2020 Feb; 87(2):109-120. PubMed ID: 32015064 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]